{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-11-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "letter_date": "11/13/2026",
      "approver_title": null,
      "file_name": "CRL_BLA761524_20261113.pdf",
      "letter_year": "2026",
      "approval_status": "Unapproved",
      "approver_name": "Center for Drug Evaluation and Research",
      "approver_center": [],
      "company_rep": "Darshan Gandhi",
      "company_address": "601 Brickell Key Drive, Suite 1000\nMiami, FL 33131",
      "company_name": "Summit Therapeutics Inc.",
      "text": "¢ yy U.S. FOOD & DRUG\n\nADMINISTRATION\n\nBLA 761524\nCOMPLETE RESPONSE\n\nSummit Therapeutics Inc.\n\nAttention: Darshan Gandhi\n\nAssociate Director, Regulatory Affairs\n601 Brickell Key Drive, Suite 1000\nMiami, FL 33131\n\nDear Darshan Gandhi:\n\nPlease refer to your biologics license application (BLA) dated and received\nNovember 14, 2025, and your amendments, submitted under me)\n\nfor AK112/SMT112 (also referred to by the Applicant as\nivonescimab).\n\nWe have completed our review of this application, as amended, and have determined\nthat we cannot approve this application in its present form. We have described our\nreasons for this action below and, where possible, our recommendations to address\nthese issues.\n\nCLINICAL/STATISTICAL\n\nSubstantial evidence of effectiveness is not established and the benefit-risk profile does\nnot support approval.\n\n1. The applicability of the prespecified primary endpoint of progression-free survival\n(PFS) to the US population cannot be established as 93% of events (257 of 275\nPFS events) occurred in patients enrolled in China. As communicated at the\nType A meeting (March 2023) and reaffirmed at the Pre-BLA meeting (May\n2025), the Agency had previously discussed concerns regarding the enrollment\napproach for the clinical trial, which was originally designed as a single country\ntrial with enrollment exclusively in China and subsequently modified to include\nenrollment from North America (NA) and the European Union (EU). The trial\nenrolled (\" patients in China (60% of the study population) from January 2022\nto November 2022, and enrollment of patients from NA and EU regions did not\ncommence until May 2023.\n\n2. The primary endpoint of PFS, while statistically significant, demonstrated a\nmodest improvement in median PFS in the context of an add-on to\nchemotherapy, with no statistically significant improvement in final overall\nsurvival (OS) and no substantial difference in overall response rate (ORR).\n\nReference ID: 5904014\n\nBLA 761524\nPage 2\n\n3. The submitted post-hoc analyses of PFS and OS based on longer follow-up are\nexploratory only with post-hoc analyses of OS further limited by differential data\ncutoff (DCO) dates across regions. These differential DCO dates appear to be\ndue to termination of follow-up at an earlier date for patients enrolled in China\ncompared to patients enrolled in NA and EU, with clinical sites in China closing\nduring 2025.\n\n4. The modest improvement in median PFS does not outweigh the risks of\nivonescimab as an add-on to chemotherapy, given that patients with EGFR-\nmutated non-small cell lung cancer treated with ivonescimab would be exposed\nto additional toxicities, including serious immune-related toxicities and toxicities\nrelated to VEGF inhibition.\n\nRecommendation: Submit results from a new adequate and well-controlled multiregional\nclinical trial consistent with ICH E17 and FDA guidance for industry, Considerations for\nGenerating Clinical Evidence from Oncology Multiregional Clinical Development\nPrograms, demonstrating a statistically significant and clinically meaningful\nimprovement in overall survival, progression-free survival or another endpoint that\nmeasures Clinical benefit, sufficient to outweigh the observed toxicity profile. We\nrecommend you meet with us prior to initiating a new trial to discuss the proposed study\ndesign and endpoints.\n\nPRESCRIBING INFORMATION\n\nWe reserve comment on the proposed labeling until the application is otherwise\nadequate. We encourage you to review the labeling review resources on the\nPrescription Drug Labeling Resources! and Pregnancy and Lactation Labeling Final\nRule? websites, including regulations and related guidance documents and the Selected\nRequirements for Prescribing Information (SRPI) - a checklist of important format items\nfrom labeling regulations and guidances.\n\nCARTON AND CONTAINER LABELING\n\nWe reserve comment on the proposed labeling until the application is otherwise\nadequate.\n\nPROPRIETARY NAME\n\nPlease refer to our correspondence dated February 10, 2026, which addresses the\nproposed proprietary name, |). This name was found conditionally acceptable\npending approval of the application in the current review cycle. Please resubmit the\n\n1 https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources\n\n2 https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-\nfinal-rule\n\nU.S. Food and Drug Administration\n\nSilver Spring, MD 20993\n\nwww.fda.gov\n\nReference ID: 5904014\n\nBLA 761524\nPage 3\n\nproposed proprietary name when you respond to all of the application deficiencies that\nhave been identified in this letter.\n\nSAFETY UPDATE\n\nWhen you respond to the above deficiencies, include a safety update. The safety\nupdate should include data from all nonclinical and clinical studies/trials of the product\nunder consideration regardless of indication, dosage form, or dose level.\n\n5.\n\n6.\n\n10.\n\n11.\n\nDescribe in detail any significant changes or findings in the safety profile.\n\nWhen assembling the sections describing discontinuations due to adverse\nevents, serious adverse events, and common adverse events, incorporate new\nsafety data as follows:\n\ne Present new safety data from the studies/clinical trials for the proposed\nindication using the same format as in the original submission.\n\ne Present tabulations of the new safety data combined with the original\napplication data.\n\ne Include tables that compare frequencies of adverse events in the original\napplication with the retabulated frequencies described in the bullet above.\n\ne For indications other than the proposed indication, provide separate tables for\nthe frequencies of adverse events occurring in Clinical trials.\n\nPresent a retabulation of the reasons for premature trial discontinuation by\nincorporating the drop-outs from the newly completed trials. Describe any new\ntrends or patterns identified.\n\nProvide case report forms and narrative summaries for each subject who died\nduring a Clinical trial or who did not complete a trial because of an adverse event.\nIn addition, provide narrative summaries for serious adverse events.\n\nDescribe any information that suggests a substantial change in the incidence of\ncommon, but less serious, adverse events between the new data and the original\napplication data.\n\nProvide updated exposure information for the clinical studies/trials (e.g., number\nof subjects, person time).\n\nProvide a summary of worldwide experience on the safety of this product. Include\nan updated estimate of use for product marketed in other countries.\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5904014\n\nBLA 761524\nPage 4\n\n12. Provide English translations of current approved foreign labeling not previously\nsubmitted.\n\nOTHER\n\nWithin one year after the date of this letter, you are required to resubmit or take other\nactions available under 21 CFR 601.3(b). If you do not take one of these actions, we\n\nmay consider your lack of response a request to withdraw the application under\n\n21 CFR 601.3(c). You may also request an extension of time in which to resubmit the\napplication.\n\nA resubmission must fully address all the deficiencies listed in this letter and should be\nclearly marked with \"RESUBMISSION\" in large font, bolded type at the beginning of the\ncover letter of the submission. The cover letter should clearly state that you consider\nthis resubmission a complete response to the deficiencies outlined in this letter. A partial\nresponse to this letter will not be processed as a resubmission and will not start a new\nreview cycle.\n\nYou may request a meeting or teleconference with us to discuss what steps you need to\ntake before the application may be approved. If you wish to have such a meeting,\nsubmit your meeting request as described in the draft guidance for industry Formal\nMeetings Between the FDA and Sponsors or Applicants of PDUFA Products.\n\nThe product may not be legally marketed until you have been notified in writing that this\napplication is approved.\n\nNOTICE REGARDING PUBLIC DISCLOSURE\n\nConsistent with FDA's public statements regarding its Complete Response Letter\ndisclosure initiative, the Agency is working to redact and publish this Complete\nResponse Letter on the FDA website, as appropriate. Should this Complete Response\nLetter be publicly disclosed, FDA will redact trade secret information, confidential\ncommercial information, and personally identifiable information consistent with 21 CFR\nPart 20 prior to publication.\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5904014\n\nBLA 761524\n\nPage 5\nIf you have any questions, contact\n\nSincerely,\n\n{See appended electronic signature page}\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\n\nReference ID: 5904014\n\nSignature Page 1 of 1\n\nThis is a representation of an electronic record that was signed\nelectronically. Following this are manifestations of any and all\nelectronic signatures for this electronic record.\n\n(b) (4)\n\n11/13/2026 02:08:40 PM\n\nReference ID: 5904014\n",
      "application_number": [
        "BLA 761524"
      ],
      "letter_type": "COMPLETE RESPONSE"
    }
  ]
}